- Home
- GMM vs LUNG Comparison
GMM vs LUNG Comparison
Compare GMM & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMM
- LUNG
- Stock Information
- Founded
- GMM 2017
- LUNG 1995
- Country
- GMM China
- LUNG United States
- Employees
- GMM N/A
- LUNG N/A
- Industry
- GMM
- LUNG Industrial Specialties
- Sector
- GMM
- LUNG Health Care
- Exchange
- GMM Nasdaq
- LUNG Nasdaq
- Market Cap
- GMM 57.9M
- LUNG 63.6M
- IPO Year
- GMM 2023
- LUNG 2020
- Fundamental
- Price
- GMM $1.95
- LUNG $2.00
- Analyst Decision
- GMM
- LUNG Buy
- Analyst Count
- GMM 0
- LUNG 7
- Target Price
- GMM N/A
- LUNG $6.81
- AVG Volume (30 Days)
- GMM 23.9K
- LUNG 6.3M
- Earning Date
- GMM 08-18-2025
- LUNG 11-12-2025
- Dividend Yield
- GMM N/A
- LUNG N/A
- EPS Growth
- GMM N/A
- LUNG N/A
- EPS
- GMM 1.79
- LUNG N/A
- Revenue
- GMM $48,171,048.00
- LUNG $90,549,000.00
- Revenue This Year
- GMM N/A
- LUNG $10.30
- Revenue Next Year
- GMM N/A
- LUNG $14.72
- P/E Ratio
- GMM $1.09
- LUNG N/A
- Revenue Growth
- GMM 41.74
- LUNG 18.24
- 52 Week Low
- GMM $1.69
- LUNG $1.47
- 52 Week High
- GMM $7.23
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- GMM 48.08
- LUNG 60.35
- Support Level
- GMM $1.83
- LUNG $1.72
- Resistance Level
- GMM $1.95
- LUNG $2.89
- Average True Range (ATR)
- GMM 0.09
- LUNG 0.19
- MACD
- GMM 0.01
- LUNG 0.04
- Stochastic Oscillator
- GMM 66.70
- LUNG 35.04
About GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.